Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

189.24 +0.83 (+0.44%)
Streaming Delayed Price Updated: 9:45 AM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
57 58 Next >
News headline image
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
From Biogen Inc.
Via GlobeNewswire
News headline image
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Unusual Options Activity ↗
 
Via Benzinga
News headline image
11 Analysts Have This to Say About Biogen ↗
 
Via Benzinga
News headline image
Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit ↗
 
Via Benzinga
News headline image
Should You Buy Biogen Before a Big July Decision? ↗
Biogen stock has dropped about 40% from its record high. 
Via The Motley Fool
News headline image
Price Over Earnings Overview: Biogen ↗
 
Via Benzinga
News headline image
7 Blue-Chip Stocks Sitting in the Sweet Spot ↗
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move. 
Via InvestorPlace
News headline image
Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23 ↗
Looking for longs after a clear resumption of the uptrend. 
Via Talk Markets
News headline image
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement ↗
The companies are focusing on a small population of ALS patients with a genetic mutation. 
Via Investor's Business Daily
News headline image
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder ↗
 
Via Benzinga
News headline image
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States 
From Biogen Inc.
Via GlobeNewswire
News headline image
(BIIB) - Analyzing Biogen's Short Interest ↗
 
Via Benzinga
News headline image
Biogen's Debt Overview ↗
 
Via Benzinga
News headline image
1 Reason to Buy Biogen Stock, and 1 Reason to Sell ↗
It could be a make or break year for the biotech. 
Via The Motley Fool
News headline image
iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach ↗
Interested in investing in iMetabolic BioPharma? Click here to get started! 
Via Benzinga
News headline image
7 Healthcare Stocks to Buy for Long-Term Growth and Stability ↗
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023. 
Via InvestorPlace
News headline image
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo ↗
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. 
Via Benzinga
News headline image
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year ↗
 
Via Benzinga
News headline image
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments ↗
 
Via Benzinga
News headline image
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
From Biogen Inc.
Via GlobeNewswire
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for... 
Via FinancialNewsMedia
News headline image
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity ↗
 
Via Benzinga
News headline image
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies, 
Via MarketBeat
News headline image
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone ↗
 
Via Benzinga
News headline image
Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed ↗
The company is definitively closing the door on solanezumab. 
Via Investor's Business Daily
News headline image
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock ↗
Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule. 
Via InvestorPlace
News headline image
Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8 ↗
Looking for a bottom in wave {v} to then look for longs. 
Via Talk Markets
News headline image
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
From Biogen Inc.
Via GlobeNewswire
News headline image
Why Shares of Anavex Life Sciences Rose 12.4% in February ↗
The company's first-quarter earnings report detailed positive news regarding its pipeline. 
Via The Motley Fool
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.